[Current status of castration-resistant prostate cancer translational research]

Area of Science:

• Oncology
• Translational Research

Background:

• Castration-resistant prostate cancer (CRPC) poses a significant clinical challenge.
• While abiraterone and enzalutamide offer new treatment options, a subset of patients exhibit primary resistance, and most eventually develop secondary resistance.

Purpose of the Study:

• To review novel therapeutic targets and treatment-selection markers for CRPC.
• To highlight translational research on AR-V7, TMPRSS2-ERG fusion gene, and EP4 antagonists.

Main Methods:

• Literature review focusing on recent advancements in CRPC therapy.
• Analysis of translational research on specific molecular targets.

Main Results:

• Identified AR-V7, TMPRSS2-ERG fusion gene, and EP4 antagonists as promising areas for CRPC research.
• These targets represent potential strategies to overcome therapeutic resistance.

Conclusions:

• Further investigation into AR-V7, TMPRSS2-ERG, and EP4 antagonists is crucial for developing more effective CRPC treatments.
• These targets may serve as biomarkers for selecting appropriate therapies and overcoming resistance mechanisms.